Anne‐Marie Fillet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anne‐Marie Fillet has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Catherine Leport
Department of Infectious Diseases, Bichat‐Claude Bernard Hospital, Paris, France
1 shared publicationChristine Katlama
Department of Infectious Diseases, Pitié‐Salpêtrière Hospital, Paris, France
1 shared publication- Dominique Costagliola
Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France
1 shared publication Dominique Salmon
Department of Internal Medicine, Cochin Hospital, Paris, France
1 shared publicationElyanne Gault
Department of Virology, Avicenne Hospital, Bobigny, France
1 shared publicationKarine Gourlain
Department of Virology, Pitie-Salpetriere Hospital, Paris, France
1 shared publication
Latest Publications
- 13 January 2003
- Published by Wiley in Journal of Medical Virology
- Vol. 69 (3) , 401-407
Quantitation of cytomegalovirus (CMV) DNA by real‐time PCR for occurrence of CMV disease in HIV‐infected patients receiving highly active antiretroviral therapy
In HIV‐infected patients treated with highly active antiretroviral therapy (HAART) included in the Predivir cohort, we have evaluated the usefulness of CMV DNA quantitation by a TaqMan® PCR assay from peripheral blood leukocytes (PBLs) to predict CMV disease occurrence. In parallel with the immune restoration after treatment by HAART, the percentage of positive samples decreased progressively from 7.3% at Day 0 to 3.5% at Month 12. Among the CMV markers, the smallest concordance with PBL CMV TaqMan® PCR, as evaluated by kappa, was observed with pp65 antigenemia, whereas concordance with all other CMV markers was high. Among the 16 patients with CMV DNA copies at least once >100/150,000 cells, CMV disease occurred in six during follow‐up, whereas among the 159 patients with CMV DNA copies always 10 and 10/150,000 cells (RR: 27.6, IC95: 7.1–107.2), the CD4 cell count 100,000 copies/ml were predictive for CMV disease. In a stepwise multivariate analysis, which should be interpreted with caution due to the small number of events (n = 10), three covariates were associated independently with CMV disease: pp65 antigenemia >100 nuclei/200,000, PBL CMV TaqMan® PCR >10 copies/150,000 cells and HIV viral load remaining or increasing >100,000 copies/ml. J. Med. Virol. 69:401–407, 2003.
- 13 January 2003
- Published by Wiley in Journal of Medical Virology
- Vol. 69 (3) , 401-407
Quantitation of cytomegalovirus (CMV) DNA by real‐time PCR for occurrence of CMV disease in HIV‐infected patients receiving highly active antiretroviral therapy
In HIV‐infected patients treated with highly active antiretroviral therapy (HAART) included in the Predivir cohort, we have evaluated the usefulness of CMV DNA quantitation by a TaqMan® PCR assay from peripheral blood leukocytes (PBLs) to predict CMV disease occurrence. In parallel with the immune restoration after treatment by HAART, the percentage of positive samples decreased progressively from 7.3% at Day 0 to 3.5% at Month 12. Among the CMV markers, the smallest concordance with PBL CMV TaqMan® PCR, as evaluated by kappa, was observed with pp65 antigenemia, whereas concordance with all other CMV markers was high. Among the 16 patients with CMV DNA copies at least once >100/150,000 cells, CMV disease occurred in six during follow‐up, whereas among the 159 patients with CMV DNA copies always 10 and 10/150,000 cells (RR: 27.6, IC95: 7.1–107.2), the CD4 cell count 100,000 copies/ml were predictive for CMV disease. In a stepwise multivariate analysis, which should be interpreted with caution due to the small number of events (n = 10), three covariates were associated independently with CMV disease: pp65 antigenemia >100 nuclei/200,000, PBL CMV TaqMan® PCR >10 copies/150,000 cells and HIV viral load remaining or increasing >100,000 copies/ml. J. Med. Virol. 69:401–407, 2003.